NEJM Evidence’s Post

Transforming Allergy Research: The BAMSE Project Story In the face of a rising allergy epidemic in Sweden, the Karolinska Institute's BAMSE Project revolutionised allergy research. Tracking 4,000 children since 1994, they've achieved a remarkable 75% response rate, thanks to switching from mail to digital surveys with Questback.   "With the digital shift using Questback, we've seen a dramatic change in our research dynamics. It's not just about efficiency; it's about reaching deeper, more meaningful conclusions faster and more reliably," says André Lauber, IT coordinator at the Institute of Environmental Medicine - Karolinska Institutet.   🚀 Impact: This approach not only streamlined data collection but also played a crucial role during COVID-19, offering vital insights into how allergies affect virus susceptibility.   Read the whole business case here: https://lnkd.in/d3289NPj

Regulating the polarization of macrophages in allergies can be achieved through the influence of noncoding RNAs. Discover more about this topic by reading the article at the following link: https://buff.ly/3tmRAdZ. Gain insights into how noncoding RNAs play a role in determining the behavior of macrophages in allergic reactions. Stay informed and keep up with the latest developments in the field of allergy research. #AllergyResearch #MacrophagePolarization

Our pioneering #peanutallergy research using the SEQ SIFTER™ discovery platform to interrogate IgE producing B-cells marks a significant milestone in the IgGenix journey to revolutionize the treatment of severe allergies through the development of monoclonal antibodies. We're currently gearing up to enter the clinic with our first program in peanut allergy, but this is just the beginning. At IgGenix, we are focused on unlocking IgE biology in a new way to push the boundaries of what's possible in #allergyresearch for allergies and IgE mediated disease. We believe in a future where living with severe allergies doesn't mean living in fear. Learn more about our work: https://iggenix.com/ #TeamIgGenix

22 years ago, in November 2001, the connection between allergy and asthma was documented and published by the World Health Organization (WHO). Allergic rhinitis and its impact on asthma was investigated, and a spotlight was put on the importance of accurate diagnosis and personalised treatment plans. The link was documented by a working group of 37 leading allergologists from all over the world. Senior Vice President of Global Pharmacovigilance & Clinical Development at ALK, Martin Rud Pedersen, says: "The discovery in 2001 was a pivotal moment in the history of allergy care. It provided documentation on the link between allergy and asthma, and it included a recommended global programme for improved diagnoses and treatment of allergy. It hereby laid the foundation for a transformation that improved the lives of people with allergy." Ever since the foundation of ALK in 1923, the focus of our company has been on exactly that; improving the lives of people living with allergy. The ARIA report – which was the title of the momentous publication – was an important milestone on our continued journey, which we have been on for 100 years. It has had a significant impact on our ability to help people with allergy to an even greater extend. #allergy #asthma #pharma #innovation #science #ARIAreport

https://lnkd.in/ebwazYmE Pediatricians, allergists, general practitioners, lab directors, and med techs: Register today to join your peers for Allergy Science Day 2024. Learn about the relationship between allergies and cancer, the effect of climate change, the impact of cross-reactive carbohydrate determinants, and the comparability of allergy assays.

The first volume of the Journal of Allergy and Hypersensitivity is now officially complete! 🚀 Explore the diverse range of articles featured in this inaugural volume: - Not just another klass (JAK) of inhibitors for allergie - Anaphylaxis and adrenaline auto-injectors: what do pharmacists know? - IgE-mediated egg allergy in children: Diagnosis and management - Unraveling determinants of severe anaphylaxis — A cluster analysis from a large national hospitalization database - What Canadians search about asthma: a 10-year Google Trends study on asthma and related topics As an open access journal, all articles are freely accessible to everyone. 👉🏻 Remember that all accepted articles in the first years will be waived!! Don’t miss the opportunity to document your results: https://lnkd.in/g8vE_j_c We extend our deepest gratitude to all the authors for their invaluable contributions. 🙏 Available on the French society of allergy or on the Elsevier’s website https://lnkd.in/esBhCBpw #openaccess #jahd #revue #allergy #hypersensitivity

Peanuts have always posed a serious risk for babies with peanut allergies, but a groundbreaking new program aims to transform allergy care. 🤝John Hunter Children’s Hospital is one of 10 paediatric hospitals to have partnered with the National Allergy Centre of Excellence (NACE) and the Murdoch Children's Research Institute - MCRI to introduce the first nationwide peanut oral immunotherapy program. 🥜Babies with a peanut allergy will be offered oral immunotherapy, to help them build a tolerance to peanuts and potentially achieve remission. The free program is available to babies under 12 months, diagnosed with a peanut allergy, and who are under the care of an allergist at one of the participating hospitals. Together, we are working towards a future where peanuts pose no threat to our little ones. 👉 Learn more: https://shorturl.at/ZJvr8 #ChildHealth #PeanutAllergy #OralImmunotherapy #AllergyResearch

https://lnkd.in/gZk3tuXQ Pediatricians, allergists, general practitioners, lab directors, and med techs: Register today to join your peers for Allergy Science Day 2024. Learn about the relationship between allergies and cancer, the effect of climate change, the impact of cross-reactive carbohydrate determinants, and the comparability of allergy assays.

This week marks Allergy Awareness Week in the UK, a time to reaffirm our commitment to pioneering treatments for those living with #allergies and immune-related disorders and to reflect on why we conduct our research. Allergy is the most common chronic disease in Europe, affecting more than 150 million people. Allergy UK predicts that by 2026, 1 in 2 of us will be living with an #allergy. Against this backdrop, our research into next-generation allergy immunotherapies is more important than ever. We are working hard to develop a potential vaccine for #peanutAllergy which, if successful, could generate a paradigm shift in how this chronic condition is managed. And our short-course grass pollen immunotherapy candidate has the potential to deliver a step change in the treatment of the most common cause of #hayfever. These are just two examples of our commitment to transform the lives of people living with allergies by breaking new ground in #immunology research, and we look forward to updating the allergy community on our progress. To learn more about #AllergyAwarenessWeek: https://lnkd.in/eywJurYx #grassAllergy #allergyAwareness #tooBigToIgnore

https://lnkd.in/d93ywnQ9 Pediatricians, allergists, general practitioners, lab directors, and med techs: Register today to join your peers for Allergy Science Day 2024. Learn about the relationship between allergies and cancer, the effect of climate change, the impact of cross-reactive carbohydrate determinants, and the comparability of allergy assays.